Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-6363
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEggebrecht, Lisa-
dc.contributor.authorLudolph, Paul-
dc.contributor.authorGöbel, Sebastian-
dc.contributor.authorPanova-Noeva, Marina-
dc.contributor.authorArnold, Natalie-
dc.contributor.authorNagler, Markus-
dc.contributor.authorBickel, Christoph-
dc.contributor.authorLauterbach, Michael-
dc.contributor.authorHardt, Roland-
dc.contributor.authorten Cate, Hugo-
dc.contributor.authorLackner, Karl J.-
dc.contributor.authorEspinola-Klein, Christine-
dc.contributor.authorMünzel, Thomas-
dc.contributor.authorProchaska, Jürgen H.-
dc.contributor.authorWild, Philipp S.-
dc.date.accessioned2021-09-24T08:04:59Z-
dc.date.available2021-09-24T08:04:59Z-
dc.date.issued2021-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/6373-
dc.description.abstractTo evaluate the cost-saving of a specialized, eHealth-based management service (CS) in comparison to regular medical care (RMC) for the management of patients receiving oral anticoagulation (OAC) therapy. Costs of hospitalization were derived via diagnosis-related groups which comprise diagnoses (ICD-10) and operation and procedure classification system (OPS), which resulted in OAC-related (i.e. bleeding/ thromboembolic events) and non-OAC-related costs for both cohorts. Cost for anticoagulation management comprised INR-testing, personnel, and technical support. In total, 705 patients were managed by CS and 1490 patients received RMC. The number of hospital stays was significantly lower in the CS cohort compared to RMC (CS: 23.4/100 py; RMC: 68.7/100 py); with the most pronounced difference in OAC-related admissions (CS: 2.8/100 py; RMC: 13.3/100 py). Total costs for anticoagulation management amounted to 101 EUR/py in RMC and 311 EUR/py in CS, whereas hospitalization costs were 3261 [IQR 2857–3689] EUR/py in RMC and 683 [504–874] EUR/py in CS. This resulted in an overall cost saving 2368 EUR/py favoring the CS. The lower frequency of adverse events in anticoagulated patients managed by the telemedicine-based CS compared to RMC translated into a substantial cost-saving, despite higher costs for the specialized management of patients.en_GB
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleCost saving analysis of specialized, eHealth-based management of patients receiving oral anticoagulation therapy : results from the thrombEVAL studyen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-6363-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleScientific reportsde
jgu.journal.volume11de
jgu.pages.alternative2577de
jgu.publisher.year2021-
jgu.publisher.nameMacmillan Publishers Limited, part of Springer Naturede
jgu.publisher.placeLondonde
jgu.publisher.urihttps://doi.org/10.1038/s41598-021-82076-9de
jgu.publisher.issn2045-2322de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
jgu.publisher.doi10.1038/s41598-021-82076-9
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
eggebrecht_lisa-cost_saving_an-20210922194241777.pdf1.29 MBAdobe PDFView/Open